Skip to main content

Epithalamin vs CJC-1295

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Epithalamin

Epithalamin is a natural peptide extract from the pineal gland. It is the precursor compound from which the synthetic Epitalon was derived. Known for anti-aging and telomerase-activating properties.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

AspectEpithalaminCJC-1295
MechanismSimilar to Epitalon, it stimulates telomerase production and may help maintain telomere length. Also regulates melatonin synthesis and circadian rhythms.CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical DosageResearch dosing: 10-20mg daily for 10-20 day cycles. Often administered 1-3 times per year in long-term protocols.CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
AdministrationIntramuscular or subcutaneous injection. Natural extract may have more variable composition than synthetic Epitalon.Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side EffectsGenerally well-tolerated. May affect sleep patterns. Less characterized than synthetic Epitalon.Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For

What They Have in Common

Both Epithalamin and CJC-1295 are commonly used for:

Key Differences

Unique to CJC-1295:

Detailed Analysis

Both CJC-1295 and Epithalamin are commonly used for Sleep Quality.

Which Should You Choose?

Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.

Ready to Learn More?